Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The aims of the trial are (1) to determine the tolerability rate in the setting of a
multi-centre study and (2) to determine secondary tolerability endpoints, toxicity rates and
complete pathologic response rate in patients with locally advanced rectal cancer who are
treated with an integrated preoperative radiotherapy with FOLFOX chemotherapy regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Trans Tasman Radiation Oncology Group Trans-Tasman Radiation Oncology Group (TROG)